These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 14559833

  • 1. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
    Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP, Imai K.
    Cancer Res; 2003 Oct 01; 63(19):6432-41. PubMed ID: 14559833
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
    Adachi Y, Lee CT, Carbone DP.
    Novartis Found Symp; 2004 Oct 01; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
    [Abstract] [Full Text] [Related]

  • 4. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines.
    Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP.
    Gastroenterology; 2002 Oct 01; 123(4):1191-204. PubMed ID: 12360481
    [Abstract] [Full Text] [Related]

  • 5. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.
    Lee CT, Park KH, Adachi Y, Seol JY, Yoo CG, Kim YW, Han SK, Shim YS, Coffee K, Dikov MM, Carbone DP.
    Cancer Gene Ther; 2003 Jan 01; 10(1):57-63. PubMed ID: 12489029
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45.
    Li H, Adachi Y, Yamamoto H, Min Y, Ohashi H, Ii M, Arimura Y, Endo T, Lee CT, Carbone DP, Imai K, Shinomura Y.
    Cancer; 2011 Jul 15; 117(14):3135-47. PubMed ID: 21264842
    [Abstract] [Full Text] [Related]

  • 7. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y, Li R, Yamamoto H, Min Y, Piao W, Wang Y, Imsumran A, Li H, Arimura Y, Lee CT, Imai K, Carbone DP, Shinomura Y.
    Carcinogenesis; 2009 Aug 15; 30(8):1305-13. PubMed ID: 19493905
    [Abstract] [Full Text] [Related]

  • 8. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
    Cancer Res; 2001 Sep 15; 61(18):6747-54. PubMed ID: 11559546
    [Abstract] [Full Text] [Related]

  • 9. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M.
    Cancer Res; 2003 Oct 15; 63(20):6726-34. PubMed ID: 14583467
    [Abstract] [Full Text] [Related]

  • 11. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.
    Cancer Sci; 2012 Feb 15; 103(2):252-61. PubMed ID: 22044563
    [Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM.
    Cancer Res; 2007 Feb 01; 67(3):1155-62. PubMed ID: 17283150
    [Abstract] [Full Text] [Related]

  • 13. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice.
    Jetzt A, Howe JA, Horn MT, Maxwell E, Yin Z, Johnson D, Kumar CC.
    Cancer Res; 2003 Oct 15; 63(20):6697-706. PubMed ID: 14583464
    [Abstract] [Full Text] [Related]

  • 14. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ, Kong MJ, Ma ZY, Qian JF, Fan JQ, Xu XH.
    Zhonghua Yi Xue Za Zhi; 2007 Jun 05; 87(21):1506-9. PubMed ID: 17785094
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, He QY, Cheung AL.
    Clin Cancer Res; 2014 May 15; 20(10):2651-62. PubMed ID: 24599933
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M, Li H, Adachi Y, Yamamoto H, Ohashi H, Taniguchi H, Arimura Y, Carbone DP, Imai K, Shinomura Y.
    Clin Cancer Res; 2011 Aug 01; 17(15):5048-59. PubMed ID: 21642381
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma.
    Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, Piao W, Nosho K, Arimura Y, Shinomura Y, Hosokawa M, Lee CT, Carbone DP, Imai K.
    Carcinogenesis; 2007 May 01; 28(5):947-56. PubMed ID: 17183068
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M, Schillaci R, Proietti CJ, Carnevale R, Frahm I, Molinolo AA, Iribarren A, Charreau EH, Elizalde PV.
    Oncogene; 2004 Jul 01; 23(30):5161-74. PubMed ID: 15122317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.